Search / Trial NCT06224010

Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS

Launched by UNIVERSITY OF TURIN, ITALY · Jan 23, 2024

Trial Information

Current as of October 09, 2024

Completed

Keywords

Ards Covid 19 Weaning From Mechanical Ventilation Respiratory Drive Inspiratory Effort Respiratory Monitoring

Description

Multicenter cohort study in four Italian ICU including adults with moderate and severe CARDS (PaO2/FiO2 \<100 mmHg) at ICU admission. An historical cohort of patients with ARDS from various etiologies used for comparison. Respiratory drive (P0.1), diaphragm electrical activity (EAdi), inspiratory effort derived from EAdi (∆PmusEAdi) and from deflection in airway pressure occluded (ΔPocc) (PmusΔPocc), dynamic transpulmonary driving pressure (ΔPL,dyn, the difference between peak and end-expiratory transpulmonary pressure) measured under assisted ventilation. The main ventilatory pattern vari...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients with a diagnosis of acute respiratory distress syndrome based on the Berlin criteria.
  • * Patients with ARDS due to confirmed COVID-19 through real-time RT-PCR on nasopharyngeal swabs or lower respiratory tract aspirates.
  • * Patients who had received invasive mechanical ventilation for more than 72 hours.
  • * Patients who were candidates for assisted ventilation.
  • Readiness for assisted ventilation, which was defined by the following criteria:
  • 1. Improvement of the condition leading to acute respiratory failure.
  • 2. Positive end-expiratory pressure lower than 10 cmH2O and inspiratory oxygen fraction lower than 0.5.
  • 3. Richmond agitation sedation scale score between 0 and -3.
  • 4. Ability to trigger the ventilator, i.e., decrease pressure airway opening by more than 3-4 cmH2O during a brief (5-10 seconds) end-expiratory occlusion test.
  • * Hemodynamic stability without vasopressor or inotropes, except for dobutamine and norepinephrine infusion below certain thresholds (dobutamine \<5 gamma/Kg/min and norepinephrine \<0.3 gamma/Kg/min).
  • * Normothermia.
  • Exclusion Criteria:
  • * Patients affected by neurological or neuromuscular pathology and/or known phrenic nerve dysfunction.
  • * Patients with any contraindication to the insertion of a nasogastric tube, such as recent upper gastrointestinal surgery or esophageal varices.
  • * Patients \< 18 years old

About University Of Turin, Italy

The University of Turin, located in Italy, is a prestigious academic institution renowned for its commitment to research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive expertise and resources to advance scientific knowledge and improve patient outcomes. Collaborating with a network of healthcare professionals and researchers, the University of Turin conducts rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its focus on translational research ensures that findings contribute to the development of effective therapies and healthcare solutions, enhancing the overall well-being of diverse populations.

Locations

Turin, , Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0